Biome Australia (BIO) AGM 2025 summary

Opening remarks and agenda

• Directors and auditor introduced; meeting opened with all voting to be conducted by poll.

• Company secretary appointed as returning officer; proxies representing 55,361,178 shares validated.

• Notice of meeting taken as read; financial statements for year ended 30 June 2025 tabled for discussion.

Financial performance review

• FY 2025 sales reached AUD 10.4 million, with a 41% increase to AUD 18.4 million compared to FY 2024.

• Achieved net profit for the year, maintaining a 61% gross margin and positive cash flow in Q1 FY 2026.

• Q4 FY 2025 and Q1 FY 2026 both set sales records, with Q1 revenue at nearly AUD 6 million and a run rate of AUD 24 million.

• Pharmacy sell-through for FY 2025 was around 50%, with growth driven by same store sales.

• Cash receipts in Q1 FY 2026 reached AUD 7.14 million, up 84% year on year.

Board and executive committee updates

• Resolution proposed and passed for re-election of Geoffrey Sam as Director.